

IMMUCELL CORP /DE/  
Form 8-K  
April 23, 2003

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

April 22, 2003

---

(Date of earliest event reported)

**IMMUCELL CORPORATION**

---

(Exact name of registrant as specified in its charter)

0-15507

---

(Commission file number)

DELAWARE

---

(State or other jurisdiction of incorporation)

01-0382980

---

(I.R.S. Employer Identification No.)

56 Evergreen Drive

Portland, ME 04103

---

(Address of principal executive offices and zip code)

(207) 878-2770

---

(Registrant's telephone number, including area code)

---

**Item 7. Financial Statements and Exhibits**

- (a) Not applicable
- (b) Not applicable
- (c) Exhibits

99.1 Press release of Company dated April 22, 2003

**Item 9. Regulation FD Disclosure (Information furnished pursuant to Item 12, Results of Operations and Financial Condition ).**

On April 22, 2003, ImmuCell Corporation (the Company ) issued a press release announcing earnings results for the quarter ended March 31, 2003. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.

In accordance with the procedural guidance in SEC Release No. 33-8216, the information in this Form 8-K and the Exhibit attached hereto is being furnished under Item 9. Regulation FD Disclosure rather than under Item 12. Results of Operations and Financial Condition. The information shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934 (the Exchange Act ) or otherwise subject to liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 of the Exchange Act, except as expressly set forth by specific reference in such a filing.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

IMMUCELL CORPORATION

Date April 23, 2003  
Michael F. Brigham

/s/ Michael F. Brigham

President and Chief Executive Officer

**EXHIBIT INDEX**

<b>Exhibit No.</b>	<b>Description of Exhibit</b>
99.1	Press release of the Company dated April 22, 2003